ROSEN, SKILLED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before ...

robot
Abstract generation in progress

The Rosen Law Firm is encouraging investors of REGENXBIO, Inc. (NASDAQ: RGNX) who purchased securities between February 9, 2022, and January 27, 2026, to secure legal counsel before the April 14, 2026, lead plaintiff deadline. The firm highlights its experience in securities class action litigation and notes that a class action lawsuit has already been filed, alleging that REGENXBIO made misleading statements about its product candidate RGX-111. Investors are advised that their ability to share in any future recovery is not dependent on serving as lead plaintiff.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin